4-methoxy-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid | 1242427-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 4-methoxy-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid
• CAS: 1242427-43-5
• 化学式: C₉H₈N₂O₃
• 分子量: 192.174
• InChiKey: SUSOHPOJQNSHAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  75.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-methoxy-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid 在 氢溴酸 、 溶剂黄146 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (1S,3aR,6aS) N-[(2S)-4-hydroxy-3-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-{4-oxo-1H,5H-pyrrolo[3,2-c]pyridine-2-carbonyl}hexahydro-1H-cyclopenta[c]pyrrole-1-carboxamide
  参考文献：
  名称：

  [EN] ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS
  [FR] COMPOSÉS ANTIVIRAUX POUR LE TRAITEMENT D'INFECTIONS À CORONAVIRUS, PICORNAVIRUS ET NOROVIRUS

  摘要：

  本文提供了式（I）的化合物或其药用盐，包括包含本文描述的化合物（包括本文描述的化合物的药用盐）的药物组合物以及合成这些化合物的方法。本文还提供了使用式（I）的化合物或其药用盐治疗冠状病毒、皮科病毒和诺如病毒感染的方法。

  公开号：

  WO2021252491A1

文献信息

• [EN] RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DE VIRUS À ARN ET LEURS UTILISATIONS
  申请人：UNIV ALBERTA

  公开号：WO2022133588A1

  公开（公告）日：2022-06-30

  The present disclosure provides compounds of formula (I) and methods for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection, such as rhinovirus, coxsackievirus, norovirus and coronavirus. Aspects of the present disclosure also include methods of treating a virus infection in a subject. The human coronavirus can be Severe Acute Respiratory Syndrome coronavirus 2 (SARS-Co V-2), Severe Acute Respiratory syndrome coronavirus 1 (SARS-Co V-l) and Middle Eastern Respiratory syndrome-related coronavirus (MERS- CoV).

  本公开提供式(I)化合物和抑制病毒感染的方法，如巴尔的摩第四组RNA病毒感染，如鼻病毒，柯萨奇病毒，诺如病毒和冠状病毒。本公开还涉及在受试者中治疗病毒感染的方法。人类冠状病毒可以是严重急性呼吸综合症冠状病毒2（SARS-CoV-2），严重急性呼吸综合症冠状病毒1（SARS-CoV-1）和中东呼吸综合症相关冠状病毒（MERS-CoV）。
• Inhibitors of cysteine proteases and methods of use thereof
  申请人：Pardes Biosciences, Inc.

  公开号：US11174231B1

  公开（公告）日：2021-11-16

  The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.

  本公开提供了带有弹头的化合物及其在治疗医学疾病或失调（如病毒感染）中的用途。提供了药物组合物和制造各种带弹头化合物的方法。这些化合物可用于抑制蛋白酶，如 3C、CL 或 3CL 样蛋白酶。
• ANTI-VIRAL COMPOUNDS
  申请人：Aligos Therapeutics, Inc.

  公开号：US20220009903A1

  公开（公告）日：2022-01-13

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
• RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF
  申请人：The Governors of the University of Alberta

  公开号：US20220204476A1

  公开（公告）日：2022-06-30

  The present disclosure provides compounds and methods for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection, such as rhinovirus, coxsackievirus, norovirus and coronavirus. Aspects of the present disclosure also include methods of treating a virus infection in a subject.
• [EN] INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CYSTÉINE PROTÉASES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：PARDES BIOSCIENCES INC

  公开号：WO2021252644A1

  公开（公告）日：2021-12-16

  The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease. Formula II